actinium has been researched along with Neuroendocrine Tumors in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 8 (88.89) | 2.80 |
| Authors | Studies |
|---|---|
| Kavanal, AJ; Khosla, D; Mittal, BR; Satapathy, S; Sood, A | 1 |
| Bruchertseifer, F; Budlewski, T; Król, ZJ; Majkowska-Pilip, A; Morgenstern, A; Wierzba, W | 1 |
| Harris, PE; Zhernosekov, K | 1 |
| Bal, C; Chandekar, KR; Satapathy, S | 1 |
| Bischoff, E; Clift, R; Guest, M; Han, G; Hwang, E; Kim, D; Li, G; Lin, F; Moran, S | 1 |
| Baum, RP; Kulkarni, HR; Zhang, J | 2 |
| Das, CK; Kavanal, AJ; Mittal, BR; Satapathy, S; Sood, A | 1 |
| Bruchertseifer, F; Fahrer, J; Fottner, C; Graf, F; Huelsenbeck, J; Kaina, B; Maus, S; Miederer, M; Morgenstern, A; Schreckenberger, M; Venkatachalam, S; Weber, MM | 1 |
2 review(s) available for actinium and Neuroendocrine Tumors
| Article | Year |
|---|---|
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Topics: Actinium; Gallium Radioisotopes; Humans; Neuroendocrine Tumors; Octreotide; Quality of Life; Radioisotopes; Radiopharmaceuticals | 2022 |
Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: Actinium-225-DOTATATE and Combined Therapies.
Topics: Actinium; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms | 2023 |
7 other study(ies) available for actinium and Neuroendocrine Tumors
| Article | Year |
|---|---|
Subclinical Hypothyroidism After 225Ac-DOTATATE Therapy in a Case of Metastatic Neuroendocrine Tumor: Unknown Adverse Effect of PRRT.
Topics: Actinium; Humans; Hypothyroidism; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radionuclide Imaging | 2022 |
Innovative radioisotope therapy for patients with neuroendocrine tumors using an α (225Ac) emitter labeled somatostatin analog: octreotate. A promising new treatment for advanced progressive neuroendocrine neoplasms.
Topics: Actinium; Humans; Neuroendocrine Tumors; Radioisotopes; Somatostatin | 2022 |
RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer.
Topics: Actinium; Humans; Lung Neoplasms; Neuroendocrine Tumors; Octreotide; Small Cell Lung Carcinoma; Somatostatin | 2023 |
Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy.
Topics: Actinium; Aged; Beta Particles; Disease Progression; Female; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Receptors, Peptide; Treatment Outcome | 2020 |
225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.
Topics: Actinium; Humans; Neuroendocrine Tumors; Octreotide; Receptors, Somatostatin; Yttrium Radioisotopes | 2021 |
Alpha Before Beta: Exceptional Response to First-Line 225Ac-DOTATATE in a Patient of Metastatic Neuroendocrine Tumor With Extensive Skeletal Involvement.
Topics: Actinium; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radionuclide Imaging | 2022 |
DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
Topics: Actinium; Alpha Particles; Animals; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Breaks, Double-Stranded; Lutetium; Neuroendocrine Tumors; Radioisotopes; Rats; Receptors, Somatostatin | 2014 |